Effect of Ramelteon on middle-of-the-night balance in older adults with chronic insomnia

Journal of Clinical Sleep Medicine

Volumn 5, Issue 1, 2009, Pages 34-40

  Zammit, Gary ^a   Wang Weigand, Sherry ^b   Rosenthal, Murray ^c   Peng, Xuejun ^b  

^a Clinilabs Inc   (United States)

^b TAKEDA PHARMACEUTICALS   (United States)

^c CALIFORNIA CLINICAL TRIALS   (United States)

Author keywords

Balance; Elderly; Melatonin receptor agonist; Memory; Stability; Zolpidem

Indexed keywords

PLACEBO; RAMELTEON; ZOLPIDEM;

AGED; ARTICLE; BALANCE IMPAIRMENT; BEDTIME DOSAGE; BODY EQUILIBRIUM; CHRONIC DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG INDUCED HEADACHE; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; FALL RISK; FEMALE; HUMAN; INSOMNIA; MALE; MAXIMUM PLASMA CONCENTRATION; MEMORY DISORDER; NAUSEA; PHYSICAL MOBILITY; PSYCHOMOTOR DISORDER; RANDOMIZED CONTROLLED TRIAL; SHORT TERM MEMORY; SIDE EFFECT; SINGLE DRUG DOSE; SOMNOLENCE; TIME; WORD RECOGNITION;

EID: 61449154558     PISSN: 15509389     EISSN: 15509397     Source Type: Journal    
DOI: 10.5664/jcsm.27390     Document Type: Article

References (40)

1. Foley DJ, Monjan AA, Brown SL, Simonsick EM, Wallace RB, Blazer DG. Sleep complaints among elderly persons: an epidemiologic study of three communities. Sleep 1995;18:425-32.
2. Foley D, Ancoli-Israel S, Britz P, Walsh J. Sleep disturbances and chronic disease in older adults: results of the 2003 National Sleep Foundation Sleep in America Survey. J Psychosom Res 2004;56:497-502.
3. Hill EL, Cumming RG, Lewis R, Carrington S, Le Couteur DG. Sleep disturbances and falls in older people. J Gerontol A Biol Sci Med Sci 2007;62:62-6.
4. National Safety Council. Report on injuries in America. National Safety Council. http://www.nsc.org/lrs/statinfo/99report.htm. Last updated 1999.
5. Ancoli-Israel S, Cooke JR. Prevalence and comorbidity of insomnia and effect on functioning in elderly populations. J Am Geriatr Soc 2005;53(7 Suppl):S264-S271.
6. Schubert CR, Cruickshanks KJ, Dalton DS, Klein BE, Klein R, Nondahl DM. Prevalence of sleep problems and quality of life in an older population. Sleep 2002;25:889-93.
7. Pollock BG, Perel JM, Reynolds CF. Pharmacodynamic issues relevant to geriatric psychopharmacology. J Geriatr Psychiatry Neurol 1990;3:221-8.
8. Glass J, Lanctot KL, Herrmann N, Sproule BA, Busto UE. Sedative hypnotics in older people with insomnia: meta-analysis of risks and benefits. BMJ 2005;331:1169-73.
9. Barbee JG. Memory, benzodiazepines, and anxiety: integration of theoretical and clinical perspectives. J Clin Psychiatry 1993;54(Suppl):86-97.
10. O'Hanlon JF. Residual effects on memory and psychomotor performance of zaleplon and other hypnotic drugs. Prim Care Companion J Clin Psychiatry 2002;4(Suppl 1):38-44.
11. Mintzer MZ, Griffiths RR. Selective effects of zolpidem on human memory functions. J Psychopharmacol 1999;13:18-31.
12. Roehrs T, Merlotti L, Zorick F, Roth T. Sedative, memory, and performance effects of hypnotics. Psychopharmacology 1994;116:130-4.
13. Wang PS, Bohn RL, Glynn RJ, Mogun H, Avorn J. Hazardous benzodiazepine regimens in the elderly: effects of half-life, dosage, and duration on risk of hip fracture. Am J Psychiatry 2001;158:892-8.
14. Wagner AK, Zhang F, Soumerai SB, et al. Benzodiazepine use and hip fractures in the elderly: who is at greatest risk? Arch Intern Med 2004;164:1567-72.
15. Wang PS, Bohn RL, Glynn RJ, Mogun H, Avorn J. Zolpidem use and hip fractures in older people. J Am Geriatr Soc 2001;49:1685-90.
16. King Pharmaceuticals Inc. Sonata [package insert]. 2003. Bristol, TN.
17. Sanofi-Synthelabo Inc. Zolpidem [package insert]. 2005. New York, NY.
18. Eszopiclone (Lunesta), a new hypnotic. Med Lett Drugs Ther 2005;47:17-9.
19. Kato K, Hirai K, Nishiyama K, et al. Neurochemical properties of ramelteon (TAK-375), a selective MT1/MT2 receptor agonist. Neuropharmacol 2005;48:301-10.
20. Dubocovich ML, Rivera-Bermudez MA, Gerdin MJ, Masana MI. Molecular pharmacology, regulation and function of mammalian melatonin receptors. Front Biosci 2003;8:d1093-d1108.
21. Greenblatt DJ, Harmatz JS, Karim A. Age and sex effects on the pharmacokinetics and pharmacodynamics of ramelteon, a hypnotic agent acting via melatonin receptors MT1 and MT2. J Clin Pharmacol 2007;47:485-96.
22. Roth T, Seiden D, Sainati S, Wang-Weigand S, Zhang J, Zee P. Effects of ramelteon on patient-reported sleep latency in older adults with chronic insomnia. Sleep Med 2006;7:312-8.
23. Roth T, Seiden D, Wang-Weigand S, Zhang J. A 2-night, 3-period, crossover study of ramelteon's efficacy and safety in older adults with chronic insomnia. Curr Med Res Opin 2007;23:1005-14.
24. Zammit G, Wang-Weigand S, Peng X. Use of computerized dynamic posturography to assess balance in older adults after night-time awakenings using zolpidem as a reference. BMC Geriatrics 2008;8:15.
25. Whitney SL, Marchetti GF, Schade AI. The relationship between falls history and computerized dynamic posturography in persons with balance and vestibular disorders. Arch Phys Med Rehabil 2006;87:402-7.
26. Wallmann HW. Comparison of elderly nonfallers and fallers on performance measures of functional reach, sensory organization, and limits of stability. J Gerontol A Biol Sci Med Sci 2001;56:M580-M583.
27. NeuroCom International I. Objective Quantification of Balance and Mobility. NeuroCom International, Inc. http://www.onbalance.com/program/ role/cdp/index.aspx. Last updated 2007. Accessed September 26, 2007.
28. NeuroCom International I. Step Quick Turn Protocol. NeuroCom International, Inc. http://www.onbalance.com/neurocom/protocols/ functionalLimitation/sqt.aspx. Last updated 2007. Accessed September 26, 2007.
29. Centers for Disease Control and Prevention. Web-based injury statistics query and reporting system (WISQARS). http://www.cdc.gov/ncipc/wisqars/. Last updated 2006. Accessed July 6, 2007.
30. Magaziner J, Hawkes W, Hebel JR, et al. Recovery from hip fracture in eight areas of function. J Gerontol A Biol Sci Med Sci 2000;55:M498-M507.
31. Tinetti ME, Williams CS. The effect of falls and fall injuries on functioning in community-dwelling older persons. J Gerontol A Biol Sci Med Sci 1998;53:M112-M119.
32. Popovic JR. 1999 National Hospital Discharge Survey: annual summary with detailed diagnosis and procedure data. Vital Health Stat 13 2001;151:i-v, 1-206.
33. Roudsari BS, Ebel BE, Corso PS, Molinari NA, Koepsell TD. The acute medical care costs of fall-related injuries among the U.S. older adults. Injury 2005;36:1316-22.
34. Stevens JA, Corso PS, Finkelstein EA, Miller TR. The costs of fatal and non-fatal falls among older adults. Inj Prev 2006;12:290-5.
35. Buatois S, Gueguen R, Gauchard GC, Benetos A, Perrin PP. Posturography and risk of recurrent falls in healthy non-institutionalized persons aged over 65. Gerontology 2006;52:345-52.
36. Evans SM, Funderburk FR, Griffiths RR. Zolpidem and triazolam in humans: behavioral and subjective effects and abuse liability. J Pharmacol Exp Ther 1990;255:1246-55.
37. Rush CR, Baker RW, Wright K. Acute behavioral effects and abuse potential of trazodone, zolpidem and triazolam in humans. Psychopharmacology 1999;144:220-33.
38. Avidan AY, Fries B, James M, Szafara K, Wright G, Chervin R. Insomnia and hypnotic use, recorded in the minimum data set, as predictors of falls and hip fractures in Michigan nursing homes. J Am Geriatr Soc 2005;53:955-62.
39. Erman M, Seiden D, Zammit G, Sainati S, Zhang J. An efficacy, safety, and dose-response study of ramelteon in patients with chronic primary insomnia. Sleep Med 2006;7:17-24.
40. Zammit G, Erman M, Wang-Weigand S, Sainati S, Zhang J, Roth T. Evaluation of the efficacy and safety of ramelteon in subjects with chronic insomnia. J Clin Sleep Med 2007;3:495-504.